tezepelumab Amgen Announces Tezepelumab Biologics License Application Submitted To U.S. FDA THOUSAND OAKS, Calif., May 10, 2021 /PRNewswire/ — Amgen (NASDAQ:AMGN) today announced its partner AstraZeneca (NASDAQ:AZN) submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for tezepelumab, a potential first-in-class medicine in severe asthma. The submission is supported by positive clinical trial results from the PATHFINDER clinical program including the pivotal NAVIGATOR Phase […]

Continue reading »